Search
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA.
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380] It was later approved by the European Commission on 13 January 2022.[L39900]
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme co...
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigational[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Gabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment o...
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.